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Active case finding in tuberculosis-affected households: 
time to scale up
In 2017, 10 million people developed tuberculosis, of 
whom approximately 4 million were not diagnosed, 
treated, or notified to national tuberculosis programmes 
(NTP).1 Of the remaining 6 million, many experienced 
substantial delays in accessing and receiving appropriate 
care.1 This unacceptable situation leads to unnecessary 
disability and loss of life, and impedes tuberculosis 
control because of onward transmission at a household 
and community level. To rectify these shortcomings 
and eliminate tuberculosis, new strategies are urgently 
required to enhance tuberculosis case detection.
WHO endorses two complementary approaches to 
improve tuberculosis case detection: active case finding 
(ACF) and systematic screening of household contacts.2,3 
Household contacts of people with tuberculosis are 
a group at high risk of acquisition of tuberculosis 
infection and development of tuberculosis disease. 
Most incident tuberculosis cases within the household 
occur in the first 2 years following the diagnosis of the 
index patient.4 Household-level interventions that 
identify contacts with latent tuberculosis infection and 
tuberculosis disease and provide appropriate preventive 
therapy or treatment can break the chain of onward 
transmission.5 Thus, such interventions have the 
potential to reduce the prevalence of tuberculosis at a 
community level, especially in low-income and middle-
income countries with a high tuberculosis burden.6 In 
The Lancet Global Health, Thomas Lung and colleagues7 
report the findings of an economic evaluation 
conducted alongside a large trial of an ACF intervention 
in Vietnam.
ACT2 was a large, cluster randomised trial8 that 
recruited 25 707 household contacts of 10 964 
patients with tuberculosis in 70 districts of Vietnam.
Household contacts in intervention districts were 
invited to be screened for tuberculosis (consisting of 
physical examination, chest radiograph, and symptom 
questionnaire) at a local clinic at enrolment, then at 
6 months, 12 months, and 24 months. Household 
contacts in control districts received standard care. 
Lung and colleagues estimated the number of disability-
adjusted life years (DALYs) averted in the intervention 
group over 24 months.8
The trial results showed that, in the study sites, 
an additional 1084 registered tuberculosis cases 
(95% CI 721–1410) and 1154 (776–1495) smear positive 
tuberculosis contacts per 100 000 people were identified 
over the 24-month follow-up period in the intervention 
group compared with the control group, respectively. 
The estimated incremental cost-effectiveness ratio was 
US$544 (95% CI 330–1375) per DALY averted and the 
investigators conducted several sensitivity analyses 
around model inputs. Although these findings might 
not be generalisable to other settings—especially to low-
income countries or those with high rates of HIV and 
tuberculosis co-prevalence—the findings, nonetheless, 
remain important. ACT2 is one of the first rigorous trials 
to show that an ACF intervention integrated into NTP 
activities not only increased tuberculosis case detection 
and reduced all-cause mortality8 but was also cost-
effective. The authors conclude that ACF in tuberculosis-
affected households should be considered for wider 
implementation and scale-up in Vietnam.
Despite proven benefits and endorsement by WHO, 
ACF interventions tailored towards tuberculosis-
affected households have not been widely adopted 
or integrated into NTP activities in high-burden 
settings.9 The reasons behind this low implementation 
are complex and include health systems that have 
restricted, overstretched resources; NTPs that work 
mainly within a static model of health-care provision 
in clinics and hospitals; and tuberculosis care and 
prevention that occurs predominantly through passive 
case finding rather than active case finding, community 
engagement, and outreach. Another important factor 
underlying the gap between global policy and national-
level implementation of ACF and systematic household 
screening interventions is the lack of robust economic 
data available to NTPs to support them to make the 
most locally-appropriate decisions concerning allocation 
of resources.10 Indeed, most extant data supporting 
ACF interventions was derived from non-randomised 
observational and modelling studies, rather than 
being empirical data from pragmatic trials. Lung and 
colleagues’ research7 highlights the wider importance 
of incorporating well planned, economic evaluation 
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into the design of randomised trials, both in the field of 
tuberculosis and more widely.11
Building on this research, innovative developments 
in health economic evaluations should be assimilated 
into the planning and design of randomised trials 
addressing tuberculosis. First, analyses should go 
beyond the standard, narrow evaluation of the effect 
of interventions on health outcomes only (eg, disease-
related deaths or cases averted) and examine the effect 
on non-health outcomes. Extended cost-effectiveness 
analysis (ECEA) takes into account the effect of an 
intervention on both health and non-health outcomes, 
including out-of-pocket expenditures averted, 
financial risk protection provided, and distributional 
consequences across socioeconomic strata.12,13 ECEA is 
highly pertinent to tuberculosis given that poorer people 
are often underserved by health and social services and 
disproportionately affected by tuberculosis infection, 
disease, catastrophic tuberculosis-related costs, and 
adverse treatment outcomes.14,15 Developing simple, user-
friendly scores to estimate individual or household risk of 
tuberculosis, adverse tuberculosis clinical outcomes, or 
financial shock could ensure that potential interventions 
reach those most in need and offer the best value for 
money.16 Second, existing economic evaluations of 
interventions targeted at tuberculosis-affected house-
holds often underestimate their cost-effectiveness. This 
is mainly because health outcomes are estimated at a 
patient or individual level rather than at a household 
level, despite the household being either the unit of 
randomisation in the trial or the expressed target of an 
intervention. Other reasons for this underestimation 
are that rates of onward transmission of tuberculosis 
(either intra-household or extra-household) are not 
incorporated into calculations; duration of data collection 
or time to final follow-up is often insufficient; and, as in 
Lung and colleagues’ study,7 data on household contacts’ 
rates of tuberculosis preventive therapy or tuberculosis 
treatment completion are not frequently included in 
analyses. More accurate and representative estimates 
of household-level rather than individual-level health 
and non-health outcomes are required. Finally, ongoing 
community-based studies are now evaluating the 
broader economic consequences of ACF interventions 
from both a health system and a societal perspective, 
including mitigation of catastrophic costs of tuberculosis-
affected households (eg, the EU-funded IMPACT-TB 
project in Nepal and Vietnam) and the role of innovations 
to complement ACF, including socioeconomic support, 
empowerment, and stigma reduction for tuberculosis-
affected households (eg, the CRESIPT trial in Peru17).
In Vietnam, Lung and colleagues7 have shown 
that an NTP-delivered ACF intervention targeted 
to tuberculosis-affected households was not only 
clinically impactful but also cost-effective. This evidence 
highlights the importance of economic evaluation in 
trials and supports the potential scale-up of ACF in 
Vietnam. These findings should motivate researchers, 
implementers, and policy makers to evaluate similar ACF 
models in diverse settings.
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